Price Target Review: Bed Bath & Beyond Inc. (NASDAQ:BBBY), Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

For the current quarter, analysts are expecting Bed Bath & Beyond Inc. (NASDAQ:BBBY) to report EPS of $0.65. This consensus estimate is provided by Zacks Research. After the period that ended on 2017-02-28, Bed Bath & Beyond Inc. (NASDAQ:BBBY) reported an EPS actual of $1.84. The difference between the actual and estimate resulted in a surprise factor of 3.95%. The company is expected to release their next earnings report on or around 2017-06-28. Interested parties will be watching to see how company results compare to what the Street was projecting for the fiscal period.

Shares of Bed Bath & Beyond Inc. (NASDAQ:BBBY) have a current ABR or average broker rating of 3.29. This consensus recommendation is also provided by Zacks Research. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock.

Covering analysts often provide target price projections for company shares. The current Zacks consensus target price on shares of Bed Bath & Beyond Inc. (NASDAQ:BBBY) is $39.615. The top analyst target is $45, and the lowest target is $33 on the stock. Because of the different techniques used to gauge a company target price, estimates may be quite different from one analyst to another.

During the most recent trading session, Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares traded N/A. Tracking the stock price in relation to moving averages may provide enhanced perspective on stock performance. After a recent look, the stock has been seen trading $-0.83 off of the 50-day moving average of $10.21 and $-5.53 separated from the 200-day moving average of $14.91. Taking a further look from a different perspective, the stock has been recently recorded -75.64% off of the 52-week high of 38.50 and +12.88% apart from the 52-week low of 8.31. Monitoring stock price activity relative to moving averages and the highs and lows for the past year might help with future stock price value assessment. 

Price Target in Focus

While monitoring stock technicals is important, most investors are more concerned with where the stock might be going now.  Equity research analysts have provided views on where they believe the stock will be trading in the future. According to Thomson Reuters, sell-side analysts are projecting a consensus target price of $16.37 on company shares. This is a near-term estimate for the next 12-18 months.

Currently, Valeant Pharmaceuticals Interna has a price to earnings ratio of N/A. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The stock currently has a PEG Ratio of 0.19.

Leave a Comment